Abstract:
Osteoporosis is the most frequent metabolic disease that affects bone. Bisphosphonates, especially, alendronate sodium, are indicated as first line regimen for this disease. Alendronate is highly efficient but presents low absorption after oral administration, due to high water solubility burst release occurs. The aim of the present study was to reduce burst release and to sustain drug release from Alendronate sodium Nanoparticles containing the polymer Eudragit RLPO. The nanoparticles were prepared by Emulsion solvent evaporation technique and were characterized for mean particle size, surface charge, size distribution, drug entrapment efficiency, drug loading capacity and In vitro drug release. Drug excipients compatibility studies performed using DSC instrument indicated that there were no interactions. The results revealed that double emulsion solvent evaporation method is suitable for preparing nanoparticle formulation. The drug loading capacity of the particles varied depending on the drug polymer ratio. The mean particle size of the selected batch was 238 nm.

Keywords: Alendronate sodium, Nanoparticles, Eudragit RLPO, In vitro Release Kinetics.